Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study

(2011) Andrea Sartore-Bianchi et al.   JOURNAL OF CLINICAL PATHOLOGY

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

(2010) Lei Wu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

(2009) Andrés López-Albaitero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

(2009) William L. Dahut et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

(2009) Salvatore Siena et al.   JNCI-Journal of the National Cancer Institute

Antibody-Based Therapy for Solid Tumors

(2008) Li Yan et al.   CANCER JOURNAL

Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

(2008) N. Personeni et al.   CLINICAL CANCER RESEARCH

FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin’s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation

(2008) Mitsufumi Nishio et al.   EUROPEAN JOURNAL OF HAEMATOLOGY